Dermata Therapeutics shares rise 10.22% after-hours after $12.4M private placement to fund OTC acne kit launch.

Dermata Therapeutics (DRMA) rose 10.22% in after-hours trading, driven by the announcement of a $12.4 million private placement to fund its over-the-counter (OTC) acne kit launch and research and development. The at-the-market offering, led by H.C. Wainwright & Co., included 2.02 million shares and warrants exercisable at $2.04 per share, with company insiders participating. Proceeds will support consumer research, pre-launch activities, and strategic acquisitions, positioning the capital raise as a.